Hyperium

Rilmenidine, the active ingredient in Hyperium, is an imidazoline receptor agonist presented as an oral tablet for oral use. It is employed to lower elevated blood pressure in patients with essential hypertension. GNH USA supplies Hyperium as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Hyperium, a centrally acting antihypertensive, is indicated for conditions within the hypertension disease family. - Essential hypertension: lowers systolic and diastolic blood pressure to target levels. - Mild to moderate hypertension: provides additional control when monotherapy is insufficient. - Hypertension requiring a centrally acting agent: offers an alternative mechanism of action for patients intolerant of other classes.

Rilmenidine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dizziness - Dry mouth - Fatigue - Headache

Serious or Rare Side Effects: - Severe hypotension - Liver function abnormalities - Allergic skin reactions such as rash or angioedema

Before initiating Hyperium, several safety considerations should be observed. - Blood pressure monitoring: check regularly to avoid excessive hypotension. - Renal function assessment: adjust use in patients with impaired kidneys. - Hepatic impairment: use cautiously and monitor liver enzymes. - Elderly patients: start at lower dose and titrate slowly. - Discontinuation: avoid abrupt cessation to prevent rebound hypertension. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Rilmenidine can interact with other medicines, requiring attention to avoid harmful effects.

Major Interactions (Avoid): - Monoamine oxidase inhibitors: may cause excessive hypotension. - Other centrally acting antihypertensives (e.g., clonidine): additive blood‑pressure lowering. - Lithium: increased risk of lithium toxicity.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs: may blunt antihypertensive response. - Beta‑blockers: may enhance bradycardia and hypotension.